Journal article

Scheduled versus Pro Re Nata Dosing in the VIEW Trials

Gisbert Richard, Jordi Mones, Sebastian Wolf, Jean Francois Korobelnik, Robyn Guymer, Michaella Goldstein, Christiane Norenberg, Rupert Sandbrink, Oliver Zeitz

Ophthalmology | ELSEVIER SCIENCE INC | Published : 2015

Grants

Funding Acknowledgements

The author(s) have made the following disclosure(s): G.R.: Financial support - Bayer HealthCare (Berlin, Germany), Pfizer (Cambridge, MA), Carl Zeiss Meditec (Jena, Germany), Novartis AG (Basel, Switzerland), Pixium Vision (Paris, France); Consultant - Carl Zeiss Meditec (Jena, Germany), Pixium Vision (Paris, France).